Kathmere Capital Management’s Boston Scientific BSX Stock Holding History

Kathmere Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,420	Closed	-$215K	–	688
2026 Q1	$215K	Sell	3,420 -1,808	-35%	-$145K	0.01%	565
2025 Q4	$498K	Buy	5,228 +118	+2%	+$11.6K	0.03%	316
2025 Q3	$499K	Buy	5,110 +164	+3%	+$17K	0.04%	294
2025 Q2	$531K	Buy	4,946 +195	+4%	+$19.7K	0.04%	263
2025 Q1	$479K	Buy	4,751 +241	+5%	+$24.3K	0.04%	252
2024 Q4	$403K	Buy	4,510 +1,034	+30%	+$91K	0.04%	267
2024 Q3	$291K	Buy	3,476 +862	+33%	+$68K	0.03%	294
2024 Q2	$201K	Buy	+2,614	New	+$191K	0.02%	325

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kathmere Capital Management's BSX Position: Q2 2026 in Review

Kathmere Capital Management sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 3,420 shares — an estimated $215K sold.

Kathmere Capital Management first reported a position in BSX in Q2 2024 and held it in 8 quarters. The position peaked at $531K in Q2 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Kathmere Capital Management reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Kathmere Capital Management sold 3,420 Boston Scientific shares in Q2 2026, an estimated $215K.
Kathmere Capital Management first reported a position in Boston Scientific in Q2 2024 and held it in 8 quarters.
Kathmere Capital Management's Boston Scientific position peaked at $531K in Q2 2025.
1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.